# Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial

> **NCT05726734** · PHASE4 · UNKNOWN · sponsor: **Shanghai East Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Helicobacter Pylori Infection

## Interventions

- **DRUG:** Vonoprazan
- **DRUG:** Amoxicillin, Metronidazole
- **DRUG:** Bismuth Potassium Citrate
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT05726734
- **Lead sponsor:** Shanghai East Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02-06
- **Primary completion:** 2025-02-06
- **Final completion:** 2026-02-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05726734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05726734, "Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05726734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*